- Molecular NameDofetilide
- SynonymDofetilida [INN-Spanish]; Dofetilidum [INN-Latin]
- Weight441.573
- Drugbank_IDDB00204
- ACS_NO115256-11-6
- Show 2D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)2.45
- pka7.0; 9.0; 9.6
- LogD (pH=7, predicted)0.67
- Solubility (experiment)Very slightly soluble in water
- LogS (predicted, ACD/Labs)(ph=7)-2.34
- LogSw (predicted, AB/LogsW2.0)1.77
- Sw (mg/ml) (predicted, ACD/Labs)0.37
- No.of HBond Donors2
- No.of HBond Acceptors8
- No.of Rotatable Bonds11
- TPSA121.57
- StatusFDA approved
- AdministrationN/A
- PharmacologyA class III antiarrhythmic agent.
- Absorption_value100.0
- Absorption (description)Dofetilide is almost completely absorbed after oral administration and peak plasma concentrations are observed after 3 h. The presence of food increases the time taken to reach these concentrations but does not alter the oral bioavailability. Steady state concentrations are reached within 2 to 3 days.
- Caco_2N/A
- Bioavailability96.0
- Protein binding64.0
- Volume of distribution (VD)3.44 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIt is metabolised, in the liver, by N-oxidation and N-dealkylation to essentially inactive metabolites.
- Half life7.5 h
- ExcretionApproximately 80% of an administered dose is excreted in urine; mostly as the unchanged drug (80%) and the rest as inactive or minimal activity metabolites. No quantifiable amounts of metabolites have been detected in plasma but five have been detected in urine.
- Urinary Excretion52
- Clerance5.23 ml/min/kg
- ToxicityIn some patients, dofetilide can cause an abnormal heartbeat which in rare instances can result in death. Symptoms are fast beating of the heart, dizziness and fainting which usually occur in the first few days of treatment.
- LD50 (rat)N/A
- LD50 (mouse)N/A